eSMART Trial to Evaluate ASyMS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02356081 |
Recruitment Status :
Completed
First Posted : February 5, 2015
Last Update Posted : May 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer | Other: ASyMS intervention Group | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 829 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | eSMART: Randomised Controlled Trial to Evaluate Electronic Symptom Management Using the Advanced Symptom Management System (ASyMS) Remote Technology for Patients With Cancers |
Study Start Date : | February 2015 |
Actual Primary Completion Date : | March 31, 2019 |
Actual Study Completion Date : | March 31, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: ASyMS intervention Group
Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
|
Other: ASyMS intervention Group
ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM) |
No Intervention: Control Group
Patients in the control group will receive standard care as is currently available at their clinical site.
|
- Memorial Symptom Assessment Scale (MSAS) [ Time Frame: At the end of each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy. ]The MSAS is a multidimensional selfreport questionnaire that evaluates 32 physical and psychological symptoms according to their frequency, severity and distress/bother to the person in the past week.
- Memorial Symptom Assessment Scale (MSAS) [ Time Frame: At the halfway point during each cycle of chemotherapy (each cycle can be wither 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy and/or at 3 monthly intervals for up to one year following a maximum of 6 cycles of chemotherapy. ]The MSAS is a multidimensional self-report questionnaire that evaluates 32 physical and psychological symptoms according to their frequency, severity and distress/bother to the person in the past week.
- Functional Assessment of Cancer Therapy General (FACT-G) [ Time Frame: At the end of each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy and/or at 3 monthly intervals for up to one year following a maximum of 6 cycles of chemotherapy. ]during active chemotherapy and/or at the 1 year follow-up
- Supportive Care Needs Survey Short Form [ Time Frame: At the end of each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy and/or at 3 monthly intervals for up to one year following a maximum of 6 cycles of chemotherapy. ]The 34-item instrument measures supportive care needs in five domains: health system and information, psychological needs, physical and daily living, patient care and support, and sexual-related.
- State-Trait Anxiety Inventory-Revised [ Time Frame: At the end of each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy and/or at 3 monthly intervals for up to one year following a maximum of 6 cycles of chemotherapy. ]The STAI-R is a 40-item measure of two types of anxiety - state anxiety (anxiety about an event), and trait anxiety (anxiety level as a personal characteristic). The State Anxiety scale assesses intensity of current feelings "at this moment". The Trait Anxiety scale assesses frequency of feelings 'in general'.
- Communication and Attitudinal Self-Efficacy scale for cancer [ Time Frame: At the end of each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy and/or at 3 monthly intervals for up to one year following a maximum of 6 cycles of chemotherapy. ]A 12-item measure of cancer patients' confidence and ability to engage in their self-care (i.e. self-efficacy) contributing to 3 dimensions (maintaining a positive attitude, understanding and participating in care, seeking and obtaining information).
- Work Limitations Questionnaire [ Time Frame: At the end of each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy and/or at 3 monthly intervals for up to one year following a maximum of 6 cycles of chemotherapy. ]A 25-item measure corresponding to 4 dimensions: time management; physical; mental/interpersonal; output demands). This was only completed by those individuals who were working.
- EuroQol 5-Dimensions combined with the Client Services Receipt Inventory [ Time Frame: At the end of each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy and/or at 3 monthly intervals for up to one year following a maximum of 6 cycles of chemotherapy. ]To evaluate the cost-effectiveness of the intervention for the management of chemotherapy-related symptoms
- Changes in clinical practice as a result of the intervention [ Time Frame: Baseline and immediately after the intervention ]Exploring experiences of an anticipatory and preventative model of care
- Predictive Risk Models (PRMs) to predict patients' chemotherapy-related symptoms by combining demographic, clinical, social and health service data collected from previous studies, as well as the current study, to inform the predictions made. [ Time Frame: Daily throughout each cycle of chemotherapy (each cycle can be either 14, 21 or 28 days long) for up to a maximum of 6 cycles of chemotherapy. ]To move beyond traditional approaches to manage symptoms in oncology patients receiving chemotherapy to more tailored and anticipatory approaches.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosed with breast cancer, colorectal cancer, or haematological malignancies (i.e. HD or NHL).
- Scheduled to receive first-line cytotoxic chemotherapy.
- Scheduled to receive 2-, 3- or 4-weekly chemotherapy protocols (i.e. chemotherapy administered at repeated cycles of 14, 21 or 28 days, respectively).
- Planned to receive a minimum of 3 chemotherapy cycles.
- Deemed physically/psychologically fit to participate in the study by a member of the multidisciplinary team.
- Able to understand and communicate in the respective language.
Exclusion Criteria:
- Patients with breast cancer or colorectal cancer with a distant metastasis, i.e. stage IV disease as defined by the TNM/UICC, (at the start of their chemotherapy treatment).
- Patients with a haematological malignancy (HD or NHL), who have B symptoms, (at the start of their chemotherapy treatment).
- Scheduled to receive concurrent radiotherapy during chemotherapy treatment.
- Scheduled to receive weekly chemotherapy protocols. Also, patients who shift from a 2-, 3- or 4-weekly protocol to a weekly protocol during chemotherapy will be excluded from further participation in the study.
- Diagnosed with the same type of cancer (i.e. where relapse has occurred) AND/OR another type of cancer (the only exception non-melanoma skin cancer) within the 5 years prior to recruitment to the study.
- Received chemotherapy treatment for any medical reason within the last 5 years, unless this is chemoradiation for colorectal cancer.
- Unable to provide written informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02356081
Austria | |
Medical University Vienna Comprehensive Cancer Center | |
Vienna, Austria | |
Greece | |
Agioi Anargiri Cancer Hospital | |
Athens, Greece | |
Air Force General Hospital | |
Athens, Greece | |
Metropolitan Hospital | |
Athens, Greece | |
Ireland | |
St James's Hospital | |
Dublin, Ireland | |
St Vincent's Healthcare Group | |
Dublin, Ireland | |
Norway | |
Innlandet Hospital Trust | |
Lillehammer, Norway | |
United Kingdom | |
Guy's and St Thomas' NHS Foundation Trust | |
London, United Kingdom | |
St George's Healthcare Trust | |
London, United Kingdom | |
University College London | |
London, United Kingdom | |
Mount Vernon Cancer Centre | |
Northwood, United Kingdom |
Principal Investigator: | Roma Maguire | University of Strathclyde |
Responsible Party: | Louise McKean, Solicitor, University of Strathclyde |
ClinicalTrials.gov Identifier: | NCT02356081 |
Other Study ID Numbers: |
CRC331 |
First Posted: | February 5, 2015 Key Record Dates |
Last Update Posted: | May 26, 2021 |
Last Verified: | May 2021 |